On the other hand, our results showed that ITGB2 is sufficient and required for EGFR activation in SCLC (Figures 2, 5, 6, 7 and 8), suggesting that targeting ITGB2 may sensitize SCLC cells to EGFR-TKI treatment. The gene discussed is EGFR; the disease is small cell lung carcinoma.